Kopran Peer Comparison

NSE: KOPRAN | BSE: 524280

₹246.30

₹-15.35 (-5.87%)

As on 23-Oct-2026 15:58IST

Market cap

₹1,183 Cr

Revenue (TTM)

₹700 Cr

P/E Ratio

47.4

P/B Ratio

2.2

Div. Yield

1.2 %

Edit

	Kopran	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Market cap (₹ Cr)	1,183	29,133	24,969	25,354	23,510
Revenue (₹ Cr)	700	3,564	9,205	1,462	1,936
Net Profit (₹ Cr)	24.98	414.00	-371.81	387.35	288.22
Net Margin (%)	3.56	11.23	-3.93	26.01	14.79
RoE (%)	4.84	8.38	-3.85	25.18	29.77
Price to Earnings	47.36	71.23	--	65.65	81.57
Price-To-Book	2.21	5.79	3.12	14.69	17.51

Income Statement (₹ Cr)

	Kopran	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Operating Revenue	700.20	3,564.00	9,205.28	1,461.80	1,935.80
Total Income	702.44	3,686.00	9,449.59	1,489.25	1,948.58
Total Expenditure	638.97	2,792.00	8,195.15	919.25	1,485.56
EBITDA	61.23	772.00	1,010.13	542.56	450.24
Depreciation	18.99	226.00	857.51	37.68	50.83
EBIT	42.25	546.00	152.62	504.88	399.41
Interest	11.22	217.00	342.73	3.77	40.84
Other Income	2.24	122.00	244.31	27.45	12.78
Exceptional Items	0.00	12.00	-216.88	0.00	0.00
Profit before Tax	33.27	463.00	-162.68	528.56	371.35
Provision for Tax	8.29	49.00	209.13	141.21	83.14
Profit after Tax	24.98	414.00	-371.81	387.35	288.22

	Kopran	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Shareholder's Funds	530.28	4,940.00	8,162.62	1,653.56	1,288.82
Minority Interest	0.00	-5.00	0.00	-1.13	0.00
Non-Current Liabilities	31.90	1,712.00	5,044.14	42.40	202.03
Current Liabilities	346.18	1,622.00	4,758.28	230.82	835.87
Total Liabilities	908.36	8,578.00	17,723.32	1,983.96	2,326.71

	Kopran	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Non-Current Assets	371.29	5,343.00	10,211.52	1,026.85	519.60
Current Assets	523.18	2,606.00	7,191.66	881.27	1,681.81
Total Assets	908.36	8,578.00	17,723.32	1,983.96	2,326.71
Total Debt*	152.69	2,125.00	5,495.48	26.49	259.37
Net Current Assets	177.00	984.00	2,433.38	650.46	845.94
Contingent Liabilities	18.95	768.26	95.72	17.25	19.09

	Kopran	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Cash From Operating Activities	66.75	390.00	1,652.60	292.17	205.05
Cash Flow from Investing Activities	-64.60	-241.00	-826.03	-265.94	-409.72
Cash from Financing Activities	-20.94	-54.00	-38.98	4.10	283.07
Net Cash Inflow / Outflow	-18.79	95.00	787.59	30.33	78.39

	Kopran	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
ROCE (%)	6.65	6.79	1.24	32.42	29.22
ROE (%)	4.84	8.38	-3.85	25.18	29.77
ROA (%)	2.85	4.94	-2.21	21.93	24.77
EBIT Margin (%)	6.03	15.32	1.66	34.54	20.63
Net Margin (%)	3.56	11.23	-3.93	26.01	14.79
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Kopran	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Revenue Growth (%)	11.96	18.37	0.78	40.90	46.65
EBIT Growth (%)	-15.19	252.26	-70.53	124.50	62.13
Net Profit Growth (%)	-28.43	377.85	-1,383.43	104.15	89.49
EPS Growth (%)	-28.47	1,001.33	-484.84	42.32	78.60
Book Value Growth (%)	2.36	13.47	0.33	26.03	144.31

	Kopran	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Price / Earnings	50.50	75.69	-83.01	68.12	81.23
Price / Book Value	2.35	5.99	3.24	15.25	17.71
Dividend Yield (%)	1.15	0.00	0.00	0.08	0.10
EV/EBITDA	23.00	40.96	29.81	48.13	52.62
Market Cap (₹ Cr)	521.02	19,071.62	18,108.89	20,944.75	12,753.19

	Kopran	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Debt to Equity	0.03	0.31	0.53	0.02	0.11
Short term debt to equity ratio	0.26	0.09	0.09	0.02	0.05
Current Ratio	1.51	1.61	1.51	3.82	2.01
Quick Ratio	1.04	1.06	0.87	2.82	1.14
Interest Coverage	3.97	3.13	0.53	141.16	10.09

	Kopran	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Debtors to sales (%)	37.51	16.50	23.44	24.80	26.28
Asset Turnover	0.80	0.43	0.55	0.83	1.66
Receivable days	127.91	58.75	78.20	88.98	40.13
Inventory Days	89.35	75.82	93.30	56.04	60.29
Payable days	122.98	186.21	226.14	99.95	232.47
Cash Conversion Cycle	94.28	-51.64	-54.64	45.07	-132.04

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.